Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HE 3235

Drug Profile

HE 3235

Alternative Names: Apoptone; HE-3235

Latest Information Update: 29 Sep 2015

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hollis-Eden Pharmaceuticals
  • Developer Harbor Therapeutics
  • Class Androstanols; Antineoplastics; Hormonal steroids; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Apoptosis stimulants; Raf kinase inhibitors; Src-family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Prostate cancer

Most Recent Events

  • 29 Sep 2015 Discontinued - Phase-I/II for Prostate cancer (Hormone refractory, Late-stage disease, Treatment-experienced) in USA (PO)
  • 29 Sep 2015 Discontinued - Preclinical for Breast cancer in USA (PO)
  • 28 Feb 2011 Pharmacodynamics data from animal studies in breast cancer released by Harbor BioSciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top